About

Appointed Chief Scientific Officer effective January 2, 2024, having joined the board as a Class I director in September 2022 (resigning from the board effective January 1, 2024). Professor and Alvera L. Kan Endowed Chair of Neurological Surgery and Radiation Oncology at UCSF with 30+ years in gene therapy.

Roles

4D Molecular Therapeutics, Inc.
Chief Scientific Officer; former Director · Current role
2022–present

Also at 4D Molecular Therapeutics, Inc.

Related

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.